NCT00427687已完成1 期
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Parallel-Group Study of the Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of AGG-523 Administered Orally to Subjects With Mild to Moderate Osteoarthritis
Wyeth is now a wholly owned subsidiary of Pfizer3 个研究点 分布在 1 个国家开始时间: 2007年2月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 试验地点
- 3
- 主要终点
- The effect of AGG-523 on biomarkers related to osteoarthritis.
研究概览
简要总结
This study will evaluate the effect of AGG-523 administration on biomarkers related to osteoarthritis. Safety and tolerability of AGG-523 will also be assessed.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double
入排标准
- 年龄范围
- 40 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Mild to moderate Osteoarthritis of the target knee.
- •Subjects must be generally healthy but enrolled with stable chronic illness if well controlled.
排除标准
- 未提供
结局指标
主要结局
The effect of AGG-523 on biomarkers related to osteoarthritis.
次要结局
未报告次要终点
研究者
研究点 (3)
Loading locations...
相似试验
已完成
3 期
Active Drug Comparative, Multi-center, phase3 Clinical Study to Evaluate the Efficacy and Safety of PG201 in Osteoarthritis PatientsOsteoarthritis of the KneeNCT01576419PMG Pharm Co., Ltd309
终止
2 期
AMG 827 in Subjects With Psoriatic ArthritisPsoriatic ArthritisNCT01516957Bausch Health Americas, Inc.168
已完成
2 期
A Study of GW842166 in Adults With Osteoarthritis PainOsteoarthritis, KneeNCT00447486GlaxoSmithKline308
已完成
2 期
A Safety and Efficacy Study to Evaluate AMG 531 Treatment in Subject With Myelodysplastic Syndrome Receiving RevlimidMyelodysplastic SyndromesThrombocytopeniaNCT00418665Amgen39
已完成
3 期
Efficacy Study of PN400 (VIMOVO) Twice Daily and Celebrex Once Daily in Patients With OsteoarthritisOsteoarthritisNCT00665431POZEN610